Daniel Allen - Dec 28, 2022 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role
Director
Signature
/s/ Daniel Allen
Stock symbol
PMCB
Transactions as of
Dec 28, 2022
Transactions value $
$0
Form type
4
Date filed
12/30/2022, 03:05 PM
Previous filing
Aug 24, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMCB Stock Option (Right to Buy) Award $0 +125K $0.00 125K Dec 28, 2022 Common Stock 125K $2.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel Allen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022.